Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeStance Health (LFST) Cash & Equivalents (2021 - 2025)

Historic Cash & Equivalents for LifeStance Health (LFST) over the last 5 years, with Q3 2025 value amounting to $203.9 million.

  • LifeStance Health's Cash & Equivalents rose 9870.68% to $203.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $203.9 million, marking a year-over-year increase of 9870.68%. This contributed to the annual value of $154.6 million for FY2024, which is 9609.64% up from last year.
  • According to the latest figures from Q3 2025, LifeStance Health's Cash & Equivalents is $203.9 million, which was up 9870.68% from $188.9 million recorded in Q2 2025.
  • In the past 5 years, LifeStance Health's Cash & Equivalents ranged from a high of $276.2 million in Q2 2021 and a low of $42.6 million during Q3 2023
  • In the last 5 years, LifeStance Health's Cash & Equivalents had a median value of $105.6 million in 2022 and averaged $124.2 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first crashed by 6499.26% in 2022, then skyrocketed by 17165.48% in 2025.
  • Over the past 5 years, LifeStance Health's Cash & Equivalents (Quarter) stood at $148.0 million in 2021, then decreased by 26.62% to $108.6 million in 2022, then fell by 27.43% to $78.8 million in 2023, then soared by 96.1% to $154.6 million in 2024, then surged by 31.92% to $203.9 million in 2025.
  • Its last three reported values are $203.9 million in Q3 2025, $188.9 million for Q2 2025, and $134.3 million during Q1 2025.